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Abstract
Previous studies have shown that human liver stem-like cells (HLSCs) may undergo differentiation in vitro into urea producing
hepatocytes and in vivo may sustain liver function in models of experimentally induced acute liver injury. The aim of this study
was to assess the safety of HLSCs intrahepatic administration in inherited neonatal-onset hyperammonemia. The study was
approved by the Agenzia Italiana del Farmaco on favorable opinion of the Italian Institute of Health as an open-label, prospective,
uncontrolled, monocentric Phase I study (HLSC 01–11, EudraCT-No. 2012–002120-33). Three patients affected by
argininosuccinic aciduria (patient 1) and methylmalonic acidemia (patients 2 and 3) and included in the liver transplantation list
were enrolled. In all patients, HLSCswere administered by percutaneous intrahepatic injections (once a week for two consecutive
weeks) within the first months of life. The first patient received 125,000 HLSCs x gram of liver/dose while the other two patients
received twice this dose. No immunosuppression was administered since HLSCs possess immunomodulatory activities. None of
the patients experienced infections, hyperammonemia decompensation, or other adverse events during the whole observation
period. No donor specific antibodies (DSA) against HLSCs were detected. Patients were metabolic stable despite an increase
(~30%) in protein intake. Two patients underwent liver transplantation after 19 and 11 months respectively, and after explanta-
tion, the native livers showed no histological alterations. In conclusion, percutaneous intrahepatic administration of HLSCs was
safe in newborn with inherited neonatal-onset hyperammonemia. These data pave the way for Phase II studies in selected
inherited and acquired liver disorders.
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Introduction
Long-term medical management of neonatal-onset
hyperammonemia due to urea cycle disorders (UCDs) or
organic acidemias (OAs) requires dietary restrictions, or-
phan medications and intensive clinical monitoring, which
have a strong negative effect on the quality of life of
patients. In spite of conventional treatment, acute meta-
bolic decompensations, comorbidity, and disappointing
deadly prognosis hamper the clinical course of these dis-
orders [1]. To face this severe prognosis, liver transplan-
tation has been growingly indicated in UCDs and OAs
(mostly methylmalonic acidemia), with successful preven-
tion of metabolic decompensations, improved clinical
prognosis, and amelioration of quality of life [2–6]. In
newborns, however, bridging strategies to liver transplan-
tation are necessary to prevent metabolic sequelae in the
pre-transplantation window and to optimize the overall
clinical outcome. Hepatocyte transplantation was intro-
duced in 1997 and attempted in various inborn errors of
metabolism with transient metabolic effectiveness [7–9].
Either fresh or cryopreserved hepatocytes isolated from a
liver donor were administered via the portal vein to cor-
rect the inherited enzyme deficiency. However, several
issues complicated the feasibility and safety of liver trans-
plantation in the clinical practice, including shortage of
donor livers, the quality of cryopreserved cells, the need
for invasive procedures to perform portal infusions, limit-
ed space in the native liver, the risk of extra-hepatic
spread of transplanted hepatocytes (mostly to the lung),
limited engraftment of transplanted cells and the need of
immunosuppression to prevent rejection. These limita-
tions led to an increased interest in the potential use of
stem cells with hepatic differentiation capability [10].
Human liver stem-like cells (HLSCs) are a mesenchymal-
like progenitor cell population with self-renewing capability
derived from human adult liver tissue [11]. HLSCs express
some hepatocyte markers such as albumin, cytokeratin 8 and
alpha-fetoprotein, some mesenchymal stem cells markers
(CD73, CD29, CD90, CD105) and some embryonic markers
(Nanog, Oct 3/4, Musashi1) [11, 12]. In vitro,HLSCs showed
multiple differentiation potentials, including differentiation in-
to mature hepatocyte [12] and pancreatic islet-like organoid
differentiation [13]. In vivo, HLSCs were shown to increase
survival in a lethal model of fulminant liver failure and to
restore liver function [12].
The main objective of this Phase I study in newborns suf-
fering from inherited neonatal-onset hyperammonemia was
that to assess the clinical safety of HLSCs intrahepatic admin-
istration The secondary objective of HLSC treatment was to
evaluate short- and long-term clinical, biochemical outcomes,
and the maintenance of patient metabolic stability in view of
liver transplantation.
Material and Methods
Isolation, Culture and Characterization of HLSCs
The study was approved by the Agenzia Italiana del Farmaco
(AIFA) on the basis of approvals the local ethics committee and
the Italian Institute of Health as an open-label, prospective, un-
controlled, monocentric Phase I study (HLSC 01–11, EudraCT-
No. 2012–002120-33). HLSCs were manufactured according to
the requirements of the Directive 2001/20/EC by Areta interna-
tional (Gerenzano, Italy). The HLSCs master cell bank was ob-
tained from a donor liver belonging to the category of standard
risk, as described in the Italian National Transplant Centre
Guidelines (batch n° SL-13-001, retest date: November 2015;
batch n° SL-13-001, retest date: December 2015; batch n° SL-
15-001, retest date:March 2018; batch n° SL-15-002, retest date:
March 2018). A complete record of the batch numbers and ex-
piry dates of the study drug was maintained in the Trial Master
File. Figure 1 depict the sequential steps involve in the generation
of the GMP master cell bank and the final product. The valida-
tion of the mater cell bank has been detailed described in the
Investigational Medicinal Product Dossier (IMPD) presented to
the regulatory authority (AIFA) to obtain the approval of the
study. The HLSC master cell bank was generated from a human
liver fragment by a modification of the technic previously de-
scribed for the generation of the research master cell banks [11].
Briefly, the liver biopsy was digested in a solution of GMP-grade
collagenase NBI 0.6 mg/ml and 0.73 mg/ml neutral protease NB
(both from Nordmark Arzneimittel GMBH & CO.KG,
Germany) dissolved in HBSS (Lonza, Basel, Switzerland) in
the presence of 3 mM CaCl2. After 2 weeks of culture, HLSC
colonies were evident and cells were split and expanded in T175
(Greiner S.p.A, Lombardia, Italy). The medium used was alpha-
MEM (Lonza) supplemented with 10% gamma irradiated and
inactivated GMP-grade fetal calf serum (Lonza), with 2 mM L-
glutamine, 4 ng/ml human recombinant GMP-grade EGF (R&D
systems, Abington, UK) and with human recombinant GMP-
grade FGF-2 (Cellgenix GmbH, Freiburg, Germany).
HLSCs were characterized by indirect immunofluores-
cence as previously described [11]. Briefly, cells were cultured
on chamber slides (Nalge Nunc International, Rochester, NY),
fixed in 4% paraformaldehyde and permeabilized with
HEPES Triton X-100 buffer. The following primary antibod-
ies were used: anti-albumin, anti-α-fetoprotein (R&D
Systems, Abington, U.K), anti-vimentin, (Sigma-Aldrich, St.
Louis, MO), anti-nestin (Santa Cruz Biotechnology, CA,
USA), anti-nanog, anti-Oct3/4, anti-cytokeratin-8, anti-
SSEA4 (all from Abcam, Cambridge, UK), and anti-
cytokeratin-19 (Santa Cruz). Alexa Fluor 488 anti-mouse
IgG and Texas Red anti-rabbit IgG (Molecular Probes,
Leiden, The Netherlands) were used as secondary antibodies.
Confocal microscopy analysis was performed using a Zeiss
LSM 5 Pascal Model Confocal Microscope (Carl Zeiss
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International, Jena, Germany). Hoechst 33258 dye (Sigma)
was added for nuclear staining.
Cytofluorimetric analyses of HLSCswas performed using the
following antibodies phycoerythrin (PE) - or fluorescein isothio-
cyanate (FITC) -conjugated: anti-CD105, -CD29, -CD73 (all
from Miltenyi Biotec) and -CD45, -CD34 (BD Biosciences
Pharmingen, San Jose, CA) and albumin (LSBio, LifeSpan
BioSciences, Washington, USA). Population percentages and
numbers were generated for gated populations from each exper-
iment using Guava easyCyte Flow Cytometer (Millipore,
Billerica, MA, USA) and analysed with InCyte software.
In Vitro Potency Test
To test the potency of HLSC master cell bank to differentiate
into hepatocytes, HLSCs were cultured under a condition of
microgravity in the Rotary Cell Culture System (RCCS) as
described [11]. The production of urea in the supernatants
was evaluated after 4 days using QuantiChrom Urea assay kit
(BioAssay Systems, CA, USA). In this system, cells were
placed in vessels that horizontally rotate about their axis at 8–
10 rotations per minute. Cells were cultured in RCCS at a
concentration of 250,000 per millilitre in the presence of 60%
DMEM low glucose (Thermo Fisher Scientific, Waltham, MA,
USA), 40% MCDB-201, 1x insulin-transferrin-selenium, 1x
linoleic acid 2-phosphate, 10−9 M dexametasone, 10−4 ascorbic
acid 2-phosphate, hepatocyte growth factor (HGF) (10 ng/ml),
fibroblast growth factor 4 (FGF4) (10 ng/ml) all from Sigma-
Aldrich and 2% FBS (Invitrogen, Carlsbad, CA, USA). As
positive controls human hepatocyte obtained by Lonza were
used. As negative control, HLSC-derived from a patient with
argininosuccinate synthase deficiency and HLSC cultured in
adhesion in T-flask were used. The cell line that was previously
characterized expressed the same phenotype and differentiation
Fig. 1 HLSC-master cell bank generation, expansion, collection and storage of cellular suspension protocol in neonatal-onset hyperammonemia Phase I
study
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capabilities of HLSC derived from normal subjects but it has a
defective urea production [14].
In Vitro Osteogenic and Adipogenic Differentiation
HLSCs derived from the master cell bank were culture in
Osteogenic Differentiation BulletKit™ Medium (Lonza,
Basel, Switzerland) to induce osteogenic differentiation into
mature, functionally active osteoblasts as previously described
[11]. HLSCs adipogenic differentiation was also evaluated by
culturing the cells in Adipogenic Differentiation Medium
BulletKit™ Medium (Lonza) which includes both the basal
media for induction and maintenance and the necessary sup-
plements for both. Human mesenchymal stem cells (Lonza)
were used as positive control.
HLSCs Preparation and Dose Calculation
HLSCs were supplied in EVA (Ethylene Vinyl Acetate) freez-
ing bags containing 50 × 106 cells/10 ml. HLSCs were thawed
at the Cell Factory of the Centro Trapianti Cellule Staminali e
Terapie Cellulari of the Ospedale Infantile Regina Margherita
and immediately washed in thawing solution (5% albumin in a
0.9% NaCl physiological solution) to reduce DMSO concen-
tration in the suspension to a value below 0.2% (20 mg/ml),
within the limits of acceptability established by the applicable
regulations (ICH Topic Q3C (R4) “Impurities: Guideline for
Residual Solvents”). The whole procedure was performed in
class A environment, according to a validated protocol for
HLSCs processing and thawing (Protocol PV-PM-HLSC
rev.01_04.03.2013 and Report RV-PM-HLSC Rev. rev
01_24-04-2013), and to the standard operating procedure
“POS.D.1.03”. Based on preclinical results, 250,000 HLSCs
x gram of liver (equal to about 44 × 106 cells for a human
newborn bearing a 175 g liver) were assumed to be the No
Observed Adverse Effect Level (NOAEL) in rodents [12].
The recommended starting dose was established considering
the good safety profile of the treatment and previous experi-
ences with liver transplatation; therefore, a further safety fac-
tor of 50% was applied to the NOAEL dose level.
Study Design and Setting
This was an open-label, prospective, uncontrolled,
monocentric Phase I study aimed on assessing the safety of
intrahepatic administration of HLSCs in patients with
inherited neonatal-onset hyperammonemia (HLSCS 01–11,
EudraCT-No. 2012–002120-33). The enrolment period went
from January 2014 to December 2016. The study was con-
ducted by the University Hospital City of Health and Science
of Turin, Italy (Azienda Ospedaliero-Universitaria Città della
Salute e della Scienza di Torino) as non-profit sponsor.
Study Inclusion and Exclusion Criteria
Patients with neonatal-onset hyperammonemic encephalopa-
thy due to UCDs (i.e. deficiency of carbamylphosphate syn-
thetase I, ornithine transcarbamylase, argininosuccinate syn-
thetase, and argininosuccinate lyase) or OAs (i.e. deficiency of
propionyl-CoA carboxylase or methylmalonyl-CoA mutase)
were eligible for the study. Additional inclusion criteria were:
1) patients had to be referred to the Department of Pediatrics,
being referred to the “Regina Margherita” Children Hospital,
University Hospital City of Health and Science, Turin;; 2) a
favorable assessment of early liver transplantation; 3) normal
liver parenchyma and circulation as evaluated by echography
and Doppler ultrasound and 4) parental written informed con-
sent. Exclusion criteria were: 1) uncontrolled coagulopathy;2)
concurrent diseases or conditions potentially hampering com-
pliance to the study protocol. For this Phase 1 study, three
patients were allowed for enrolment by AIFA.
HLSCs Administration Protocol
Each enrolled, clinically stable patient was scheduled to re-
ceive two HLSC intrahepatic injections (once a week for two
consecutive weeks). Standard medical treatment was not
discontinued. After standardized thawing and washing (see
above), resuspended HLSCs in thawing solution at a concen-
tration of 5 × 106 cells/ml were ready for infusion. Two dosage
standards were applied according to the patients’ enrolment
order. The first patient (patient 1) received 125,000 cells x
gram of liver (about 22 × 106 cells) at each administration.
Doubled doses were scheduled in patients 2 and 3, both re-
ceiving 250,000 cells x gram of liver (about 44 × 106 cells) at
each administration. The HLSCs were percutaneously
injected into the liver parenchyma under ultrasound guidance
and local anaesthesia. All the procedure were performed in the
“Regina Margherita” Children Hospital Intensive Care Unit,
University Hospital City of Health and Science. Precautionary
hospitalization of two weeks after the first HLSCs administra-
tion was scheduled for all patients. During and after HLSCs
administrations, the patients were monitored continuously for
vital signs (temperature, heart and respiratory rates, blood
pressure, and oxygen saturation). Liver parenchyma and cir-
culation were monitored by echography and Doppler ultra-
sound, respectively. No immunosuppression was scheduled
during or after HLSCs administrations, according to the evi-
dence of HLSC immunomodulatory activity [15].
Primary (Safety), Secondary (Efficacy) Clinical,
and Biochemical Endpoints
The evaluation of the safety of intrahepatic HLSC administra-
tion in infants with inherited neonatal-onset hyperammonemia
was the primary endpoint of this study. After basal assessment
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(V0), safety data were collected daily and reviewed one week
after the first HLSC administration (V1) and one (V2) and two
weeks (V3) after the second administration (acute safety). All
patients were followed-up until present (long-term safety). All
the patients underwent clinical, biochemical, and imaging sur-
veillance addressed to the detection of hepatic and/or extra-
hepatic complications, including portal vein thrombosis,
intrahepatic hematoma, injury of the hepatic artery,
fistulisation (arterial-portal, portal-biliary or arterial-biliary),
hepatic injury and failure, liver nodular lesions, pulmonary
embolism, abdominal and/or chest haemorrhage, sepsis and
any other adverse reaction potentially dependent on the exper-
imental procedures. Histological analysis of native livers
explanted at liver transplantation time was performed.
Along with the safety assessments, different clinical and
metabolic efficacy variables were also longitudinally evaluat-
ed as secondary endpoints. The morbidity rate (defined as the
number of metabolic decompensations after HLSC therapy)
and the variation in natural protein dietary intake were the
main measures of clinical efficacy. Longitudinal assessments
of ammonia and disease-specific biochemical markers after
HLSC therapy were regarded as metabolic efficacy variables.
Results
HLSC Characterization
HLSCs expanded from the master cell bank (passage 7) were
characterized according to the criteria previously published
[11, 12, 16]. As shown in Fig. 2a, 100% of HLSCs expressed
human albumin, α-fetoprotein, and the stem cells markers
vimentin and nestin as seen by immunocytochemistry.
Moreover, approximately 30% of HLSCs expressed also
cytokeratin 8 but all the cells were negative for the oval cell
marker cytokeratin 19. As previously described, 100% of
HLSCs expressed Nanog, Oct3/4, SSEA4, (Fig. 2a) and
Sox2 and Musashi1 (not shown) embryonic stem cells
markers. By FACS analysis, HLSCs were positive for mesen-
chymal markers CD105, CD29 and CD73 but were negative
for the hematopoietic markers CD45 and CD34. The expres-
sion of albumin was also detected by FACS analysis (Fig. 2b).
As previously demonstrated for the research batches of
HLSCs [11], the GMP produced cells were shown to differ-
entiated into mature hepatocytes with production and secre-
tion of urea when cultured in hypo gravity conditions (Fig.
2c). This test was used as a potency assay for the release of the
three HLSC batches. Moreover, HLSCs were shown to under-
go in appropriated culture conditions into osteogenic differen-
tiation (Fig. 2d) similarly to mesenchymal stem cells but not
into adipogenic differentiation at variance of mesenchymal
stem cells (not shown). Chromosomal stability, absence of
tumorigenicity, viral and endotoxin negativity of the master
cell bank are reported in the IMPD. IMPD also reported tox-
icology, immunomodulatory, dosing, pharmacodynamics and
bio distribution studies performed in mice and rats using the
intra-liver administration mimicking conditions used for pa-
tient treatments.
Patient Enrolment and Treatment
During the enrolment period, three patients were diagnosed
with inherited neonatal-onset hyperammonemia at the study
Center. As they met the inclusion criteria, all these three con-
secutive patients were enrolled into the study and completed
the study protocol. Details on patients’ characteristics and
HLSC treatment are provided in Table 1. The volumes re-
quired for the administration of the scheduled HLSC dosages
by ultrasound-guided percutaneous administrations of HLSCs
(Fig. 3) ranged from 5 ml to 11 ml per dose. In all patients,
each HLSC injection lasted less than 10 min. No injection-
related complications were observed. Details of acute safety
outcomes after the HLSC administration in the three patients
are provided in Table 2. No deaths, adverse events,
intrahepatic or extrahepatic complications and no safety issues
were registered at long-term follow-up. After HLSCs admin-
istration, no signs of infections and no hyperammonemia met-
abolic decompensations were recorded in any of the three
patients. In particular, steadily normal ammonia concentra-
tions were maintained in spite of a ~30% increase in natural
protein daily intake (Figs. 4, 5, and 6, panel A and C).
Peripheral concentrations of argininosuccinic acid (ASA) in
the patient with argininosuccinic aciduria and methylmalonic
acid (MMA) in patients with methylmalonic acidemia were
stable after HLSCs injections (Figs. 4, 5, and 6, panel B). After
this plateau, a progressive increase of ASA and MMA was
invariably observed at the longitudinal follow-up (Figs. 4, 5,
and 6, panel B). After liver transplantation in patient 1 and 2,
ASA and MMA were markedly reduced (Figs. 4, 5, and 6,
panel B). Patients 1 and 2 had liver transplantation after 19 and
11 months from HLSCs administration, respectively, with no
surgical complications. After transplantation, both patients
had immunosuppressive regimen, which included basiliximab
preoperatively and on the fourth day and tacrolimus, using
therapeutic drug monitoring to reach the standard target range.
The post-transplantation course was complicated in patient 1
by two moderate acute rejections 30 days and 9 months after
transplantation, as well as the presence of donor-specific anti-
bodies (DSA) against the transplanted liver (anti DQ7 with
mean fluorescence intensity of 16,700), but not against
HLSCs. After the second episode of rejection, mycophenolate
mofetil was added with complete normalization of liver pic-
ture. The post-transplant course in patient 2 was complicated
by monomorphic Epstein Barr virus infection correlated with
post-transplant lymphoproliferative disorder, successfully
treated by rituximab. No DSA antibodies were detected in this
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patient (against either the transplanted liver or the HLSCs).
Extensive histopathological analyses of native livers removed
at transplantation revealed normal parenchyma and the ab-
sence of nodular lesions and it was not possible to identify
the exact site of HLSC injection.
Discussion
Neonatal-onset UCDs or OAs are life-threatening disorders
leading to hyperammonemic coma and requiring early spe-
cific emergency treatments [17, 18]. Patients surviving the
neonatal period experience recurrent metabolic decompensa-
tions later in life (generally triggered by undercurrent
catabolic stressors) and poor prognosis in spite of appropri-
ate long-term conventional management [1]. Liver transplan-
tation can improve the clinical outcome of patients, as it is
increasingly documented [3–6]. This evidence prompted
various clinical studies on the use of hepatocyte transplanta-
tion in various inborn errors of metabolism [7–9]. To date,
experience with hepatocyte transplantation in 22 patients
with UCDs is available [9, 19–25]. In general, hepatocyte
transplantation was shown to be transiently effective in re-
storing the deficient metabolic activity in affected patients,
providing the proof of concept of the clinical feasibility of
cellular therapies in inborn errors of metabolism.
Unfortunately, different issues hamper the clinical use of
hepa tocy te t r ansp lan ta t ion . F i r s t ly, hepa tocy te
Fig. 2 Characterization of HLSC-master cell bank. (a)Representative
confocal micrographs showing the expression of several hepatic,
mesenchymal and embryonic stem cell markers (Original magnification
at ×400). (b) Representative FACS analyses of HLSCs showing the
expression of albumin, CD105, CD29, CD73, albumin, CD45 and
CD34 (red histogram). Yellow histograms represent isotypic control.
Three experiments were performed with similar results. (c) Comparison
of urea production by the GMP master cell bank derived HLSCs with
HLSC derived from a research cell bank (HLSC6b) and HLSC derived
from argininosuccinate synthase deficient liver (HLSC-ASS) in RCCS.
Human hepatocyte were used as positive control, undifferentiated
HLSC6b (cultured in adhesion) were used as negative control Data are
expressed as mg/dL and as mean ± SD of three different experiments.
ANOVA was performed; *p < 0.05 HLSCs cultured in RCCS vs
HLSCs cultured in adhesion, #p < 0.05 GMP master cell bank derived
HLSC vs HLSC-ASS. Three experiments were performed with similar
results. (d) Osteogenic differentiation: left panel, positive staining for
calcium deposition as shown by alizarin red staining after 21 days of
culture in osteogenic differentiation medium. Right panel, negative stain-
ing for alizarin red in HLSC cultured in basal medium (original magnifi-
cation ×250). Data represent one of three experiments performed with
similar results
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transplantation requires invasive procedures for the place-
ment of a catheter into the portal vein, with the risk of dislo-
cation, thrombosis, or other surgical complications [25].
Secondly, hepatocyte transplantation requires relatively high
infusion volumes with respect to the available space in the
native liver, with an increased risk of extra-liver hepatocyte
localization. Thirdly, hepatocyte transplantation invariably
requires immunosuppressive regimen to prevent rejection
of donor cells and warrant transient metabolic effect [7, 25].
HLSCs were identified as a cell population derived from
human adult liver tissue expressing some mesenchymal and
some embryonic stem cell markers with multiple differentia-
tion and self-renewing capabilities [11, 12]. The in vitro dif-
ferentiation into mature hepatocyte was associated with urea
production [11]. Moreover, HLSC-derived extracellular vesi-
cles were shown to correct ureagenesis in an in vitro model of
argininosuccinate synthetase deficiency [14]. It has not yet
been tested whether extracellular vesicles derived from
HLSCs may correct ureagenesis deficiency in vivo.
However, it is possible that few liver engrafted HLSCs may
act in a paracrine manner trough extracellular vesicles on near-
by enzyme deficient hepatocytes transferring the relevant en-
zymes. HLSCs were shown to engraft in the liver and to be
effective in completely restoring liver function in vivo in a
model of fulminant hepat i t is developed in non-
immunocompetent mice [12]. At variance of oval cells, which
have been described in rat and mice but detectable in humans
mainly in pathological conditions [26, 27], HLSCs can easily
Table 1 Characteristics of three patients with inherited neonatal-onset
hyperammonemia due to argininosuccinate lyase (ASL) deficiency or
methylmalonic acidemia treated with percutaneous intrahepatic
administrations of human liver stem cells (HLSCs) as a bridging therapy
before liver transplantation (LT)
Patient 1 Patient 2 Patient 3
Clinical characteristics
Diagnosis ASL deficiency Methylmalonic acidemia Methylmalonic acidemia
Gene (genotype) ASL
(c.898G > T/c.913G >A)
MCM
(c.655A > T/c.927G >A)
MCM
(c.103C > T/c.785G >A)
Age at onset (days) 4 3 3
Peak ammonia (μmol/l) 709 494 757
Neonatal metabolic emergency treatment* yes yes yes
Neonatal renal replacement therapy yes yes yes
Age at Liver transplantation (months) 21 16 waiting list
HLSCs therapy
Age at treatment (months) 2 5 3
HLSCs dose: 1st administration 27 × 106 77 × 106 50 × 106
First sites of injection Left hemiliver Left hemiliver Left hemiliver
HLSCs: 2nd administration 28 × 106 79 × 106 50 × 106
Second sites of injection Right hemiliver Right hemiliver Right hemiliver
Follow-up (months) 19 11 ongoing
*ASL deficiency: protein avoidance, intravenous glucose infusion, sodium benzoate, arginine
*MMA: protein avoidance, intravenous glucose infusion, carnitine, vitamin B12
Fig. 3 Ultrasound-guided percutaneous intrahepatic injection of human
liver stem cells (HLSCs) in an infant with neonatal-onset inherited
hyperammonemia while in stable metabolic conditions. HLSCs injection
and real-time ultrasound images are presented
Stem Cell Rev and Rep
Ta
bl
e
2
B
as
al
ev
al
ua
tio
ns
(V
0)
an
d
ac
ut
e
sa
fe
ty
ou
tc
om
es
(V
1-
V
3)
in
on
e
pa
tie
nt
af
fe
ct
ed
by
ar
gi
ni
no
su
cc
in
at
e
ly
as
e
(A
S
L
)
de
fi
ci
en
cy
an
d
tw
o
pa
tie
nt
s
w
ith
m
et
hy
lm
al
on
ic
ac
id
em
ia
tr
ea
te
d
by
in
tr
ah
ep
at
ic
in
je
ct
io
ns
of
hu
m
an
liv
er
st
em
ce
lls
(H
L
SC
s)
Pa
tie
nt
1
(A
S
L
de
fi
ci
en
cy
)
P
at
ie
nt
2
an
d
3
(M
et
hy
lm
al
on
ic
ac
id
em
ia
)
A
ll
pa
tie
nt
s
H
L
SC
s
do
se
12
5,
00
0
ce
lls
/g
of
liv
er
25
0,
00
0
ce
lls
/g
of
liv
er
V
is
it
V
0
V
1
V
2
V
3
V
0
V
1
V
2
V
3
V
0
V
1
V
2
V
3
C
lin
ic
al
pa
ra
m
et
er
s
B
lo
od
pr
es
su
re
(m
m
H
g)
91
/5
2
90
/5
2
75
/4
8
72
/4
0
73
±
23
/4
3
±
23
90
±
0/
48
±
4
80
±
7/
52
±
10
85
±
7/
50
±
0
79
±
19
/4
6
±
17
90
±
0/
49
±
3
75
±
9/
48
±
10
80
±
9/
46
±
5
Te
m
pe
ra
tu
re
(°
C
)
36
.1
36
.3
36
.7
36
.0
36
.3
±
0.
1
36
.3
±
0.
1
36
.7
±
0.
7
36
.2
±
0.
2
36
.1
±
0.
1
36
.1
±
0.
6
36
.7
±
0.
2
36
.1
±
0.
2
H
ea
rt
ra
te
13
1
13
5
11
6
14
0
98
±
2
10
0
±
0
97
±
1
99
±
0
12
1
±
9
13
7
±
28
11
6
±
24
13
9
±
7
R
es
pi
ra
to
ry
ra
te
45
55
47
40
55
±
7
47
±
18
50
±
14
54
±
8
51
±
7
49
±
13
47
±
10
49
±
10
Sa
tu
ra
tio
n
O
2
(%
)
99
10
0
98
98
98
±
2
10
0
±
0
97
±
1
99
±
0
98
±
2
10
0
±
0
98
±
2
99
±
1
L
ab
or
at
or
y
te
st
s
R
ed
bl
oo
d
ce
lls
(1
01
2 /
l)
4.
0
3.
9
3.
8
4.
0
3.
6
±
0.
0
4.
4
±
0.
4
4.
4
±
0.
1
4.
4
±
0.
4
3.
7
±
0.
2
4.
3
±
0.
4
4.
2
±
0.
3
4.
3
±
0.
3
H
em
og
lo
bi
n
(g
/d
l)
10
.9
10
.0
10
.1
10
.1
7.
9
±
0.
3
10
.6
±
2.
4
9.
9
±
0.
7
9.
5
±
0.
0
8.
9
±
1.
7
10
.4
±
1.
7
9.
9
±
0.
5
9.
7
±
0.
3
P
la
te
le
ts
(1
09
/l)
72
0
57
4
76
1
45
8
76
3
±
30
48
4
±
48
58
8
±
18
6
50
2
±
38
74
9
±
33
51
4
±
62
64
5
±
16
5
48
7
±
37
W
hi
te
bl
oo
d
ce
lls
(1
09
/l)
12
.4
19
.8
12
.4
11
.8
8.
8
±
1.
6
7.
1
±
0.
3
10
.0
±
3.
4
9.
1
±
4.
6
10
.0
±
2.
2
11
.3
±
7.
3
10
.8
±
2.
7
10
.0
±
3.
6
IN
R
1.
1
1.
0
1.
0
0.
9
1.
0
±
0.
2
1.
0
±
0.
2
1.
0
±
0.
2
1.
0
±
0.
1
1.
1
±
0.
2
1.
0
±
0.
1
1.
0
±
0.
1
1.
0
±
0.
0
A
ST
(U
/l)
32
37
65
43
41
±
22
32
±
4
33
±
9
37
±
14
38
±
16
33
±
4
43
±
20
39
±
10
A
LT
(U
/l)
34
33
39
25
39
±
18
32
±
4
34
±
16
37
±
23
37
±
13
32
±
3
36
±
11
33
±
18
In
te
rn
at
io
na
ln
or
m
al
iz
ed
ra
tio
(I
N
R
,n
or
m
al
ra
ng
e
0.
8–
1.
2)
;A
sp
ar
ta
te
am
in
ot
ra
ns
fe
ra
se
(A
ST
,n
or
m
al
ra
ng
e:
20
–5
0
U
/l)
;A
la
ni
ne
am
in
ot
ra
ns
fe
ra
se
(A
LT
,n
or
m
al
ra
ng
e:
20
–5
0
U
/l)
Stem Cell Rev and Rep
be expanded and cultured from normal adult human liver [16].
Moreover, the evaluation of the telomere length during HLSC
expansion from P6 to P17 showed remarkable stability [16].
This evidence prompted us to hypothesize the use of HLSCs
as a bridging therapy until liver transplantation in patients with
inherited neonatal-onset hyperammonemia.
In this Phase I study, we investigated the clinical safety of
HLSC administration in infants with inherited neonatal-onset
hyperammonemia due to argininosuccinic aciduria or
methylmalonic acidemia. Two main original points character-
ized the introduction of HLSCs in the clinical setting and
facilitated their full safety profile. Firstly, differently from he-
patocyte transplantation, HLSCs were administered percuta-
neously into liver parenchyma under ultrasound guidance and
local anaesthesia. This mini-invasive approach was possible
because of the small injection-volumes providing the individ-
ual HLSCs scheduled doses. Besides avoiding invasive pro-
cedures and related complications, the intrahepatic injection
procedure theoretically minimizes the risk of pulmonary
spreading of transplanted cells compared to portal infusion.
Actually, no local or systemic adverse events were registered
by this approach. Secondly, no immunosuppressive regimen
was planned in patients treated with intrahepatic HLSCs. This
was based on the evidence not only of the low immunogenic-
ity of HLSCs, but also on their immunomodulatory abilities
that may potentially obviate rejection [15]. Indeed, HLSCs do
not express HLA class II or costimulatory molecules CD40,
CD80, and CD86. Moreover, HLSCs inhibit T cell prolifera-
tion and dendritic cell differentiation as also shown for mes-
enchymal stem cells [15]. In addition, HLSCs were found to
Fig. 4 Time course of ammonia
(NH3), argininosuccinic acid
(ASA), and natural protein intake
in the first enrolled patient
affected by arginine succinate
lyase (ASL) deficiency treated
with intrahepatic administrations
of human liver stem cells
(HLSCs)
Fig. 5 Time course of ammonia
(NH3), methylmalonic acid
(MMA), and natural protein
intake in the second enrolled
patient affected bymethylmalonic
acidemia due to methylmalonyl-
CoA mutase (MUT) deficiency
treated with intrahepatic
administrations of human liver
stem cells (HLSCs)
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suppress natural killer degranulation protecting them from al-
logenic lysis [15].
Short- and long-term clinical and biochemical data after
HLSCs injections were regarded as secondary endpoints. All
patients remained clinically stable and no metabolic decom-
pensations were registered after HLSCs treatment. However,
this favourable metabolic control was observed in the absence
of undercurrent catabolic stressors (i.e. febrile illnesses), thus
making difficult to correlate metabolic stability with HLSC
treatment. On the other hand, long-lasting stability of ammo-
nia concentration was maintained in all patients after HLSCs
therapy in spite of a consistent increase in dietary protein
intake. The ASAmetabolic marker of ASL deficiency (patient
1) remained stable up to 220 days whereas the MMA marker
of methylmalonic acidemia (patient 2 and 3) remained stable
up to 171 and 111 days respectively, after HLSC treatment.
However, both these disease specific metabolic markers in-
variably increased at long-term follow-up reaching maximal
levels before liver transplantation. Although the full evalua-
tion of metabolic effectiveness of HLSCs was beyond the
objective of this study, the main limitations to this purpose
are sample size, disorder heterogeneity and lack of fully reli-
able functional tools for the assessment of metabolic correc-
tion after HLSCs therapy, such as assessment of in vivo
ureagenesis not available at the time of the study. Indeed, these
issues will be addressed in upcoming studies.
All patients treated with HLSCs were enrolled on the liver
transplantationwaiting list as from the study protocol and two of
them received liver transplanted at 19 (patient 1) and 11 (patient
2) months respectively. The third patient is still in waiting list for
transplantation since the stable metabolic conditions. None of
the patients developed DSA against HLSCs despite the absence
of immunosuppression consistently with the low immunogenic-
ity of the cells. The histological examination of the native livers
removed at time of transplantation did not show any parenchy-
mal lesion confirming the bio safety of the cells and of the
administration route. The site of injection was not identifiable
not allowing identification of HLSCs in the parenchyma.
However, the progressive increase of the disease-specific meta-
bolic markers ASA and MMA suggests the absence of long-
term persistent HLSC engraftment. Since HLSC can be easily
obtainable from a small liver biopsy one can speculate to per-
form an ex vivo gene therapy to correct the enzyme defect
followed by an autologous HLSC transplantation.
In conclusion, we highlighted that percutaneous intrahepatic
administration of HLSCs is safe and well tolerated in infants
with inherited neonatal-onset hyperammonemia. The full safety
profile of this approach was facilitated by avoidance of invasive
procedures and immunosuppression. Moreover, this Phase I
study indicated that HLSC implantation in the liver did not
trigger inflammatory and immune reaction. The potential met-
abolic effect of HLSCs in inherited and acquired disorders re-
quire further studies in a larger cohort of patients and it will be
the objective of a next Phase II clinical trial.
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